炎症性肠病患者免疫调节剂单药治疗的持续使用及治疗无效发生率
该研究基于加拿大1996至2014年基于人群的炎症性肠病(IBD)数据集,评估免疫调节剂(IM)单药治疗的起始与持续使用情况、治疗无效相关结局的发生率及相关因素。结果显示,CD患者5年IM单药累积使用率为46%,UC为24.9%;约三分之一持续使用5年以上;35%的CD患者和30%的UC患者在起始IM后5年内未出现治疗无效证据。
要点
- CD患者5年IM单药累积使用率为46%,UC患者为24.9%。
- 约三分之一IM使用者持续单药治疗5年或以上。
- 35%的CD和30%的UC患者在起始IM后5年内未出现治疗无效证据。
核心结论
- 尽管多数起始IM单药治疗者停药和/或出现治疗无效证据,但相当一部分少数患者在多年治疗中未出现这些结局。
研究设计与样本
- 使用加拿大基于人群的IBD数据集,跨度1996年至2014年,评估IM单药治疗的起始与持续使用、治疗无效相关结局发生率及相关特征。
- 研究期间共纳入3312例诊断为IBD的患者(1480例CD,1832例UC)。
主要发现
- CD患者5年IM单药累积使用率为46%,UC患者为24.9%。
- 约三分之一IM使用者持续单药治疗5年或以上。
- 有皮质类固醇使用史的IM使用者中,约四分之三在起始IM后一年内皮质类固醇暴露至少减少50%。
- 35%的CD患者和30%的UC患者在起始IM后5年内未出现治疗无效证据。
- 无既往皮质类固醇使用史、无IBD住院史以及40岁后起始IM治疗的CD患者,在IM单药治疗期间发生治疗无效事件的可能性较低。
关键数值与推荐
- 治疗无效定义为IBD相关住院、IBD切除手术、全身皮质类固醇使用或需要生物制剂治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Immunomodulator (IM)-based monotherapy with thiopurines or methotrexate is being increasingly supplanted in the management of moderate-to-severe IBD by more efficacious biologic agents. However, given their low cost, IMs may still have a selective role in this setting. METHODS: We used a Canadian population-based dataset of persons with IBD spanning from 1996 until 2014 to assess the initiation and continued use of IM monotherapy, the incidence of outcomes associated with ineffectiveness (defined as IBD-related hospitalization, IBD-resective surgery, systemic corticosteroid (CS) use, or the need for biologic therapy), and the demographic and disease-related characteristics associated with persistence on IM monotherapy and IBD-associated adverse outcomes. RESULTS: There were 3312 persons diagnosed with IBD (1480 CD, 1832 ulcerative colitis (UC)) in the study period. The cumulative incidence of IM monotherapy use at 5 years was 46 % for CD and 24.9% for UC. Approximately one-third remained on IM monotherapy continuously for 5 years or more. Roughly three-quarters of IM users with a history of corticosteroid use had at least a 50% reduction in corticosteroid exposure in the year following IM initiation. Thirty-five percent of those with CD and 30% with UC had not developed evidence of therapeutic ineffectiveness within 5 years of IM initiation; people with no history of prior corticosteroid use, no IBD hospitalizations, and persons with CD initiating IM therapy after age 40 were less likely to have an episode of therapeutic ineffectiveness while on IM monotherapy CONCLUSIONS: Although the majority of persons who are initiated on IM monotherapy discontinue medications and/or have evidence of therapeutic ineffectiveness a significant minority remain free of these outcomes over many years of therapy.
引用
- Targownik LE, Leung S, Lix LM, et al. Persistence With Immunomodulator Monotherapy Use And Incidence of Therapeutic Ineffectiveness Among Users of Immunomodulator Monotherapy in IBD. Am J Gastroenterol. 2018. PMID: 29925912. doi:10.1038/s41395-018-0108-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。